The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | The management of post-MPN AML
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, talks on the management of post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML). Patients with post-MPN AML have a very poor prognosis and they are either treated with induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) or with a hypomethylating agent in combination with venetoclax, ruxolitinib or an IDH inhibitor if they are transplant-eligible, or if they are not, they are treated with agents to improve their quality of life (QoL). According to Prof. Mascarenhas, participating in clinical trials could be beneficial to these patients. This interview took place virtually.
Disclosures
Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Celgene, BMS, CTI Bio, Merck, Roche, Kartos, PharmaEssentia, Abbvie, and Geron. Consulting fees from Novartis, Incyte, CTI Bio, Constellation, Abbvie, Roche, Kartos, PharmaEssentia, Sierra Onc, Galecto, GSK, Karyopharm, Celgene, Geron and BMS.
